Point72 Asset Management L.P. Buys New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Point72 Asset Management L.P. purchased a new position in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,485,000 shares of the company’s stock, valued at approximately $5,940,000. Point72 Asset Management L.P. owned approximately 3.95% of Vigil Neuroscience at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new position in shares of Vigil Neuroscience during the second quarter valued at approximately $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Vigil Neuroscience during the 2nd quarter valued at $87,000. Renaissance Technologies LLC raised its stake in shares of Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after buying an additional 11,536 shares in the last quarter. Ensign Peak Advisors Inc raised its stake in shares of Vigil Neuroscience by 72.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after buying an additional 166,442 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Vigil Neuroscience by 11.9% in the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock valued at $3,050,000 after buying an additional 95,276 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Vigil Neuroscience Price Performance

Shares of VIGL opened at $3.35 on Wednesday. The company has a 50-day moving average of $3.57 and a two-hundred day moving average of $3.53. The stock has a market cap of $132.83 million, a price-to-earnings ratio of -1.58 and a beta of 1.96. Vigil Neuroscience, Inc. has a one year low of $2.47 and a one year high of $9.24.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.02. Analysts anticipate that Vigil Neuroscience, Inc. will post -2.15 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Guggenheim dropped their price target on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Wedbush reissued an “outperform” rating and set a $23.00 target price on shares of Vigil Neuroscience in a research note on Thursday, July 11th. Finally, HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Vigil Neuroscience in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Vigil Neuroscience currently has an average rating of “Moderate Buy” and an average price target of $16.60.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.